Our goal is the rapid medical diagnosis of inherited diseases, provided at the earliest possible moment, as we turn analytical information and insights from database intelligence into actionable results for physicians, patients and pharmaceutical partners.
Our solutions go much beyond laboratory testing and medical interpretation, leveraging our biobank, our global clinical network and deep medical expertise and our proprietary CentoCard® based sample logistics. But our state-of-the-art genetic and biomarker testing remains the core of what we do. Learn what we do in our operations, and what our global quality standards and accreditations are.
Why do we believe in genetic testing?
We are dedicated to provide the complete spectrum of genetic, biochemical and biomarker analyses. Our commitment is to convert diagnostic data rapidly into the best solution for each individual patient. With the highest quality in medical interpretation, maintained by CentoMD®, the world’s largest mutation database for rare diseases, and global data sources, we continuously develop new and innovative products in molecular diagnostics.
Whole genome sequencing identifies almost all changes in a patient’s DNA by sequencing both the entire coding and non-coding regions of the genome. CentoGenome® – our whole genome sequencing service – is the most complete solution to diagnose genetically complex and undiagnosed cases with the highest level of certainty.
Whole exome sequencing provides information on all protein-coding genes and identifies changes in DNA by focusing on the most informative regions of the genome, the exome. CentoXome® – our whole exome sequencing service – is a cost-effective solution to diagnose genetically complex and undiagnosed cases with high diagnostic rates.
NGS Panel Genomic are our most flexible and accurate gene panels with cost-effective reflex to whole-genome sequencing. These panels allow you to utilize your strong diagnostic hypothesis to reduce the cost, while benefitting from the power and upside of whole genome testing.
Our NGS panels test for a wide selection of hereditary genetic conditions. They offer a fast, thorough, and cost-effective diagnosis for patients with distinctive clinical features. The gene composition of our panels is carefully selected by our specialists based on latest publically-available information and our in-house expertise and research.
Biomarkers play an essential role in the diagnosis, prediction and therapy monitoring of several metabolic diseases, especially when patients have accessible treatment options.
CentoNIPT® offers genetic, non-invasive prenatal testing (NIPT) to screen for the most common fetal chromosomal abnormalities. Our test combines the latest next generation sequencing technology with expert medical reporting.
Prenatal diagnosis allows for the sensitive identification of disease-causing mutations in at-risk families before birth and is offered for all diseases with congenital or early onset. Prenatal testing is given the highest priority at CENTOGENE.
Comparative genomic hybridization is a molecular cytogenetic method for analyzing copy number variations. CGH array allows us to quickly and efficiently determine the relative abundance of nucleic acid sequences in the target sample.
Most people can be carriers of a disease causing change without knowing it. If both partners are carriers, they have a 25% risk of having an affected child with a recessive genetic disease and a 50% that the child will be a carrier like the parents.